EMA hands down a number of recommendations

|By:, SA News Editor

Source

Pfizer's (NYSE:PFE) Besponsa (inotuzumab ozogamicin) receives a positive recommendation from the European Medicines Agency's CHMP for the treatment of acute lymphoblastic leukaemia. The drug has orphan designation.

Biogen's (NASDAQ:BIIB) Spinraza (nusinersen) receives postive recommendation for treatment of spinal muscular atrophy.

BioMarin's (NASDAQ:BMRN) Brineura (cerliponase alfa) receives positive recommendation for treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease.

Glaxo's (NYSE:GSK) Celsentri (maraviroc) receives use extension recommendation.

Bristol-Myers' (NYSE:BMY) Opdivo (nivolumab) receives use extension recommendation.

Roche's (OTCQX:RHHBY) Avastin (bevacizumab) receives use extension recommendation.